274 related articles for article (PubMed ID: 22352336)
1. Metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir in treatment-naive, HIV type 1-infected subjects over 48 weeks.
Aberg JA; Tebas P; Overton ET; Gupta SK; Sax PE; Landay A; Falcon R; Ryan R; De La Rosa G
AIDS Res Hum Retroviruses; 2012 Oct; 28(10):1184-95. PubMed ID: 22352336
[TBL] [Abstract][Full Text] [Related]
2. Effects of once-daily darunavir/ritonavir versus atazanavir/ritonavir on insulin sensitivity in HIV-infected persons over 48 weeks: results of an exploratory substudy of METABOLIK, a phase 4, randomized trial.
Overton ET; Tebas P; Coate B; Ryan R; Perniciaro A; Dayaram YK; De La Rosa G; Baugh BP
HIV Clin Trials; 2016 Mar; 17(2):72-7. PubMed ID: 26917112
[TBL] [Abstract][Full Text] [Related]
3. Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.
Arathoon E; Schneider S; Baraldi E; Lim PL; Opravil M; Van De Casteele T; Lavreys L
Int J STD AIDS; 2013 Jan; 24(1):12-7. PubMed ID: 23440570
[TBL] [Abstract][Full Text] [Related]
4. Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir.
Martinez E; Gonzalez-Cordon A; Ferrer E; Domingo P; Negredo E; Gutierrez F; Portilla J; Curran A; Podzamczer D; Murillas J; Bernardino JI; Santos I; Carton JA; Peraire J; Pich J; Perez I; Gatell JM;
HIV Med; 2014 Jul; 15(6):330-8. PubMed ID: 24417772
[TBL] [Abstract][Full Text] [Related]
5. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
[TBL] [Abstract][Full Text] [Related]
7. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures.
Johnson M; Grinsztejn B; Rodriguez C; Coco J; DeJesus E; Lazzarin A; Lichtenstein K; Rightmire A; Sankoh S; Wilber R
AIDS; 2005 Apr; 19(7):685-94. PubMed ID: 15821394
[TBL] [Abstract][Full Text] [Related]
8. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
[TBL] [Abstract][Full Text] [Related]
9. Impact of low abundance HIV variants on response to ritonavir-boosted atazanavir or fosamprenavir given once daily with tenofovir/emtricitabine in antiretroviral-naive HIV-infected patients.
Ross LL; Weinberg WG; DeJesus E; Fischl MA; Horton JH; Pappa KA; Lancaster CT; Pakes GE; Smith KY
AIDS Res Hum Retroviruses; 2010 Apr; 26(4):407-17. PubMed ID: 20380480
[TBL] [Abstract][Full Text] [Related]
10. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F
AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection.
Elion R; Cohen C; Gathe J; Shalit P; Hawkins T; Liu HC; Mathias AA; Chuck SL; Kearney BP; Warren DR;
AIDS; 2011 Sep; 25(15):1881-6. PubMed ID: 21811136
[TBL] [Abstract][Full Text] [Related]
12. Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study.
Molina JM; Andrade-Villanueva J; Echevarria J; Chetchotisakd P; Corral J; David N; Moyle G; Mancini M; Percival L; Yang R; Wirtz V; Lataillade M; Absalon J; McGrath D;
J Acquir Immune Defic Syndr; 2010 Mar; 53(3):323-32. PubMed ID: 20032785
[TBL] [Abstract][Full Text] [Related]
13. Comparison of body composition changes between atazanavir/ritonavir and lopinavir/ritonavir each in combination with tenofovir/emtricitabine in antiretroviral-naïve patients with HIV-1 infection.
Moyle GJ; Hardy H; Farajallah A; DeGrosky M; McGrath D
Clin Drug Investig; 2014 Apr; 34(4):287-96. PubMed ID: 24557728
[TBL] [Abstract][Full Text] [Related]
14. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
[TBL] [Abstract][Full Text] [Related]
15. Effects of ritonavir-boosted darunavir vs. ritonavir-boosted atazanavir on lipid and glucose parameters in HIV-negative, healthy volunteers.
Tomaka F; Lefebvre E; Sekar V; Van Baelen B; Vangeneugden T; Vandevoorde A; Diego Miralles G
HIV Med; 2009 May; 10(5):318-27. PubMed ID: 19210693
[TBL] [Abstract][Full Text] [Related]
16. Changes in Bone Mineral Density After Initiation of Antiretroviral Treatment With Tenofovir Disoproxil Fumarate/Emtricitabine Plus Atazanavir/Ritonavir, Darunavir/Ritonavir, or Raltegravir.
Brown TT; Moser C; Currier JS; Ribaudo HJ; Rothenberg J; Kelesidis T; Yang O; Dubé MP; Murphy RL; Stein JH; McComsey GA
J Infect Dis; 2015 Oct; 212(8):1241-9. PubMed ID: 25948863
[TBL] [Abstract][Full Text] [Related]
17. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
[TBL] [Abstract][Full Text] [Related]
18. Simplification to dual-therapy containing lamivudine and darunavir/ritonavir or atazanavir/ritonavir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Calza L; Cafaggi M; Colangeli V; Borderi M; Barchi E; Lanzafame M; Nicole' S; Degli Antoni AM; Bon I; Re MC; Viale P
Infect Dis (Lond); 2018 May; 50(5):352-360. PubMed ID: 29210336
[TBL] [Abstract][Full Text] [Related]
19. Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Nishijima T; Hamada Y; Watanabe K; Komatsu H; Kinai E; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
PLoS One; 2013; 8(10):e77268. PubMed ID: 24130871
[TBL] [Abstract][Full Text] [Related]
20. Simplification from twice-daily to once-daily darunavir/ritonavir in a randomized trial among HIV-infected persons with HIV-1 RNA suppression on antiretroviral therapy.
Huhn GD; Sigman A; Livak B
Antivir Ther; 2015; 20(8):849-54. PubMed ID: 25881614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]